Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. (SYRE) is the subject of an amendment by reporting persons Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin and Tomas Kiselak reporting a lock-up agreement tied to the company’s underwritten public offering, which closed October 7, 2026. They agreed to refrain from selling Spyre securities without the underwriters’ representatives’ consent for 60 days following the October 5, 2026 final prospectus supplement. The reporting persons state that their share counts have not changed since June 23, 2026. Their disclosed securities include 812,076 common shares owned, 9,100,160 common shares issuable upon conversion of Series A Preferred Stock, and 228,646 common shares issuable upon option exercise; the disclosure excludes 4,741,640 conversion shares above the 9.99% beneficial ownership limitation. They state that they did not purchase securities or otherwise participate in the offering.
Spyre Therapeutics, Inc. (SYRE) entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the underwriters, for a public offering of 4,117,648 common shares at $85.00 per share. The underwriters received a 30-day option to purchase up to 617,647 additional shares. The offering is expected to close on or about October 7, 2026, subject to customary closing conditions. Gross proceeds to Spyre are expected to be approximately $350.0 million before underwriting discounts and commissions and estimated offering expenses. Net proceeds are intended to advance its Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness, and a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Proceeds may also support general infrastructure, potential in-licensing, acquisitions or investments in businesses, technologies, products or assets, ongoing research and development, working capital and other general corporate purposes.
Spyre Therapeutics, Inc. (SYRE) is offering 4,117,648 shares of common stock at $85.00 per share, for a total public offering price of $350,000,080.00. Estimated net proceeds are approximately $328.7 million, or approximately $378.0 million if the underwriters exercise in full their option to buy up to 617,647 additional shares. Spyre intends to use proceeds to advance its gastroenterology, rheumatology and dermatology programs, including clinical trials, manufacturing and Phase 3 readiness, and to advance SPY072 into late-stage development for HS. It also intends to use a portion for infrastructure and may use a portion for in-licensing, acquisitions or investments; remaining proceeds are for research and development, working capital and general corporate purposes.
As of June 30, 2026, Spyre had approximately $1.1 billion in cash, cash equivalents and marketable securities. Based on current business plans, it believes existing funds and offering proceeds will fund planned operations into the second half of 2029. The company estimates immediate dilution to offering purchasers of $71.51 per share, with pro forma as-adjusted net tangible book value of $13.49 per share. The underwriters expect share delivery on or about October 7, 2026.
Spyre Therapeutics, Inc. (SYRE) is conducting a preliminary primary offering of common stock, with net proceeds to the company after underwriting discounts, commissions and estimated offering expenses. Underwriters may purchase additional shares from Spyre under an option exercisable within 30 days at the public offering price, less underwriting discounts and commissions. Spyre intends to use net proceeds to advance its Gastroenterology, Rheumatology and Dermatology programs—including preclinical studies, clinical trials, manufacturing and Phase 3 readiness—and to advance SPY072 into late-stage development for hidradenitis suppurativa. It may also allocate proceeds to infrastructure, in-licensing, acquisitions or investments, research and development, working capital and general corporate purposes.
Spyre reported approximately $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026, and anticipates this balance will fund operating expenses and capital expenditures into the second half of 2029. Spyre also states that purchasers will incur immediate and substantial dilution, with potential further dilution from future equity or convertible-security issuances.
Spyre Therapeutics, Inc. Chief Legal Officer and Corporate Secretary Heidy King-Jones exercised options for 28,933 common shares at $14.50 per share on October 1, 2026, then sold 28,933 shares in five transactions under a Rule 10b5-1 trading plan adopted April 16, 2026. The sales had weighted-average prices of $89.24 (400 shares), $90.35 (16,605), $91.35 (7,228), $92.70 (2,100), and $93.46 (2,600) per share. The reported post-exercise stock-option position was 482,478 underlying shares.
Spyre Therapeutics, Inc. (SYRE) Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock on October 1, 2026, in six transactions under a Rule 10b5-1 trading plan adopted June 20, 2025. Reported per-share prices were $89.1400, $90.1000, $91.4900, $92.3100, $93.3700 and $93.9100; the first five were weighted averages.
Spyre Therapeutics, Inc. (SYRE) Chief Financial Officer Scott L. Burrows exercised options for 17,500 shares on September 30, 2026, at a $14.50 exercise price, then sold 17,500 common shares at a weighted-average $89.89 per share; prices ranged from $89.00 to $90.62. On October 1, he exercised options for 7,500 shares at $14.50 and reported five sales: 600 shares at a weighted-average $89.07 ($88.63–$89.53 range), 1,500 at $90.27 ($89.96–$90.95), 2,100 at $91.92 ($91.41–$92.26), 3,071 at $92.95 ($92.54–$93.53), and 229 at $93.57 ($93.54–$93.59). Across both dates, his reported sales covered 25,000 shares. The October 1 transactions were pursuant to a Rule 10b5-1 trading plan adopted November 10, 2025. A post-transaction amount includes 33,738 RSUs, each a contingent right to one common share upon vesting; they vest September 1, 2027, subject to continued employment.
Spyre Therapeutics, Inc. (SYRE) is named as issuer in Cameron Turtle’s Form 144 notice of a proposed sale of 45,000 common shares, with an aggregate market value of $4,006,350.00 through Morgan Stanley Smith Barney LLC. The shares are identified as previously exercised stock options dated June 15, 2023, and October 1, 2026 is listed as the approximate sale date. The notice also lists two prior sales marked 10b5-1: 15,000 shares on August 3, 2026, for $1,432,669.50 and 15,000 shares on September 1, 2026, for $1,309,413.00.
Spyre Therapeutics, Inc. (SYRE) reports that officer Heidy King-Jones proposes to sell 29,335 common shares, with an aggregate market value of $2,611,695.05, through Morgan Stanley Smith Barney LLC. The notice identifies October 1, 2026, as the approximate sale date and says the shares were and will be received through stock-option exercises over the next three months; acquisition and payment dates were and will be the dates of exercise and sale.
It also lists prior 10b5-1 sales by Heidy M. King-Jones during the past three months: 400 common shares on September 2, 2026, for $36,000.00, and 27,999 common shares on September 1, 2026, for $2,444,477.89.
Spyre Therapeutics, Inc. (SYRE) received a Schedule 13G reporting that, as of September 24, 2026, Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and managing member Senai Asefaw, M.D. each reported beneficial ownership of 4,457,450 shares, or 5.1%. Paradigm BioCapital International Fund Ltd. reported beneficial ownership of 3,928,646 shares, or 4.5%. The Fund and separately managed accounts managed by the adviser directly beneficially own the reported common stock; the adviser, its general partner, and Asefaw may be deemed to beneficially own those direct holdings. The percentages are based on 88,173,762 shares outstanding as of July 28, 2026.